Industry News

Current Good Manufacturing Practices (GMP)CGMPInspection and Compliance

Inspections help ensure the safety and quality of medicines.

FDAWe are committed to ensuring that medicines available to hospitals, healthcare systems, and patients are safe, effective, and of reliable quality. For products requiring market approval, these are typically prescription drugs.FDAThe approval process is the first step.FDAApproval of a drug application includes evaluating the manufacturing process and production facilities, and taking into account information obtained through inspection or alternative tools to ensure that the proposed manufacturing process meets applicable standards and produces high-quality drugs.

also,FDAIt also oversees the safety and quality of drugs that have not been marketed under an approved application, including over-the-counter drug information leaflets and compounded drugs.

All pharmaceuticals manufactured for the U.S. market must comply with [the relevant regulations/standards].FDAStrict standards

FDAMonitoring drugs on the market helps ensure they comply with regulations.FDARegarding safety and quality requirements, regardless of whether it is a drug application, all drugs manufactured for the U.S. market, whether produced domestically or overseas, must meet the same stringent standards.

The industry has a responsibility to comply with laws regarding drug safety and quality. Key requirements for drug manufacturing quality include the Federal Food, Drug, and Cosmetic Act (FDCA).FD&C ActRelated terms and conditionsFDACurrent Good Manufacturing Practices (GMP)CGMP)Regulation.

FDAofCGMPRequirements to ensure the safety of consumers and patients

CGMPThese requirements are meticulously designed, incorporating multi-layered processes, controls, and quality oversight, with the aim of producing high-quality medicines and detecting and rapidly mitigating potential problems before they cause harm to patients or consumers. When properly implemented, these requirements help ensure the safety, efficacy, and compliance of medicines with regulatory standards.

FDAEnhancing drug manufacturers' compliance through inspectionsCGMPRequirements. The following information describes...FDApassCGMPCheck and assess whether the drug manufacturer complies withCGMPThe document outlines the required actions and measures that can be taken when these manufacturers fail to meet regulatory standards.

FDAHow to assess and ensure compliance

CGMPexamine

Regarding post-market inspections,FDAEach year, a risk-based model is used to determine the priority of supervisory inspections. The frequency with which facilities are prioritized for inspection is based on multiple risk factors (but being selected for inspection does not necessarily indicate the presence of quality problems). Furthermore, if there is supporting information,FDAFacilities can also be inspected based on the specific circumstances.

Most manufacturers complyCGMPRequirements. In fact, more than90% The inspection revealed the facilityCGMPThe compliance is acceptable.

whenFDAWhen investigators discover problems during an inspection, they will use [the following method] at the end of the inspection.FDA 483The table records its relationship withCGMPObservations related to compliance.FDA 483The form does not constitute an indication of whether any situation is in violation.CGMPThe final ruling by the relevant body. Companies typically have...15 Within one working dayFDAVoluntary submission ofFDA 483The response to the form.

FDACompliance review

After the inspection,FDAThe following information will be reviewed:

· If issuedFDA 483sheet

· On-site inspection report written by the investigator

· Evidence collected during inspections or through the activities of other agencies

· The companyFDA 483Response to the form (if submitted to)FDA), including corrective action plans

· Other appropriate information

During the compliance review process, the organization will also consider:

· FDARequirements listed in the regulations

· Technical Standards

· Scientific advice and literature from various departments of the organization

· Overview of the manufacturing facilities and the pharmaceuticals they produce

· Risk assessment of quality deviations based on the risk of potential harm to patients or consumers.

Inspection Classification

FDAAccording to the companyCGMPThe required compliance status will categorize the inspection as acceptable or unacceptable:

· No action required (BUTThe classification indicates that the facility is in an acceptable compliance status. Typically, the facility did not receive [a certain number of] [items] at the end of the inspection.FDA 483sheet.

· It is recommended to adopt voluntary measures (ORThis classification indicates that the inspection uncovered reprehensible conditions or practices, but the organization has determined that the facility can voluntarily correct its deficiencies and will not recommend any further action. Typically, the facility receives [a certain number of] [items/performances] at the end of the inspection.FDA 483sheet.

· It is recommended to take formal action.OAIThe classification indicates that the facility is in an unacceptable compliance state.

FDAStrive to complete the inspection90 Inspection of facilities for human use of medicines to be completed within 1 dayCGMPClassification. The organization will send a letter to the facility specifying the classification (example:BUT、ORandOAI(Letters), and this category is usually published on the data dashboard.